| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
 Warning:  file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=14757842&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
 in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface Chene PMol Cancer Res  2004[Jan]; 2 (1): 20-8MDM2 inhibits p53 transcriptional activity, favors its nuclear export, and  stimulates its degradation. Inhibition of the p53-MDM2 interaction with synthetic  molecules should therefore lead to both the nuclear accumulation and the  activation of p53 followed by the death of the tumor cells from apoptosis.  Inhibitors of the p53-MDM2 interaction might be attractive new anticancer agents  that could be used to activate wild-type p53 in tumors. This review describes our  current knowledge on the properties of the existing p53-MDM2 antagonists. Because  the discovery of modulators of protein-protein interactions is an emerging field  in drug discovery, the strategy used for designing inhibitors of the p53-MDM2  interaction could serve as an example for other protein interfaces.|Animals[MESH]|Antineoplastic Agents/*pharmacology[MESH]|Binding Sites/drug effects[MESH]|Humans[MESH]|Neoplasms/*drug therapy/metabolism[MESH]|Nuclear Proteins/*antagonists & inhibitors/metabolism[MESH]|Proto-Oncogene Proteins c-mdm2[MESH]|Proto-Oncogene Proteins/*antagonists & inhibitors/metabolism[MESH]|Tumor Suppressor Protein p53/*antagonists & inhibitors/metabolism[MESH]
 |